Program
surzetoclax
In AbbVie’s pipeline, BCL-2
. Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Myeloma, led by AbbVie.
Furthest: phase 1, since Mar 25, 20222 company-led studies, 2 open or runningNext primary completion: Jul 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 22 open or running | phase 1since Mar 25, 2022 | Mar 25, 2022 | Jul 2027phase 1 · NCT06291220 |
- Named in AbbVie’s own pipeline as
Surzetoclax (ABBV-453)
, phase 1, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 25, 2022First study: phase 1 study in Multiple MyelomaFirst studyNCT05308654 · 34 enrolled · United States, Australia, Israel and more
- Feb 27, 2024Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06291220 · 4 enrolled · United States, Australia, Germany and more
Ahead
- Jul 2027Primary completion: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06291220
TargetBeta
“BCL-2”the company's pipeline, read by Claude · source
Other programs on BCL2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| venetoclaxrule | AbbVie | phase 4 | 83 |
| Bcl-2 Inhibitor TQB3909 | Sino Biopharmaceutical | phase 3 | 8 |
| lacutoclaxrule | Lupeng Pharmaceutical | phase 2 | 4 |
| surzetoclax | AbbVie | phase 2 | 3 |
| 400mg of TQB3909 tablets | Sino Biopharmaceutical | phase 2 | 1 |
| FXS0683 | Fosun Pharma | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06291220Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Germany and more | 1 | Active, not recruiting | Jul 2027 | 4 |
| NCT05308654Multiple Myeloma · United States, Australia, Israel and more | 1 | Active, not recruiting | Feb 7, 2024 | 34 |
How it is read
Names in the registry
- “ABBV-453”, 2 entries
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 study
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.